[New treatments in respiratory medicine in 2018 : asthma, cystic fibrosis and nocturnal positive pressure (CPAP or NIV)].

Abstract

In this review of novel therapies in pulmonary disorders in 2018, we cover 3 different entities. In GINA stage 1 and 2 asthma, new strategies allow a more individualized treatment. In more severe asthma, there is an increasing interest in biotherapies, with dupilumab, an anti-IL-4 receptor, completing the already available panel which includes anti-IgE, anti-IL-5 and anti-IL-5 receptor antibodies. In cystic fibrosis, a better understanding of the pathogenesis and the genetics of the disease is leading to new treatments acting directly on the function of the CFTR (Cystic fibrosis transmembrane conductance regulator), which, when used in combination, show very promising results. Finally, nocturnal positive pressure treatment (either CPAP or non invasive ventilation : NIV) is used more and more frequently. Recent studies have clarified therapeutic algorithms for the most frequent indications for NIV : COPD and obesity-hypoventilation.

• Authors: Jérôme Plojoux, Florian Charbonnier, Jean-Paul Janssens
• Journal: Revue medicale suisse (Rev Med Suisse) Vol. 15 Issue N° 632-633 Pg. 96-100 (Jan 09 2019) ISSN: 1660-9379 [Print] Switzerland
• Vernacular Title: Pneumologie: Asthme, mucoviscidose et pression positive nocturne.
• PMID: 30629379 (Publication Type: Journal Article, Review)

Topics

• Asthma (therapy)
• Continuous Positive Airway Pressure
• Cystic Fibrosis (therapy)
• Humans
• Noninvasive Ventilation
• Pulmonary Medicine (trends)